vs
Expensify, Inc.（EXFY）与RIGEL PHARMACEUTICALS INC（RIGL）财务数据对比。点击上方公司名可切换其他公司
RIGEL PHARMACEUTICALS INC的季度营收约是Expensify, Inc.的2.0倍（$69.8M vs $35.2M），RIGEL PHARMACEUTICALS INC同比增速更快（21.2% vs -4.9%），过去两年RIGEL PHARMACEUTICALS INC的营收复合增速更高（53.7% vs 2.4%）
Expensify Inc.是一家软件服务企业，主打面向个人与企业用户开发费用管理系统，助力用户便捷高效地完成费用报销、账单统计等工作，此外该公司还推出了名为Expensify Card的商务信用卡产品。
Rigel制药是一家临床阶段生物技术企业，专注于研发及商业化针对自身免疫性疾病、炎症性疾病与血液疾病的靶向小分子疗法，核心市场位于美国，旗下已获批产品可治疗成人免疫性血小板减少症，致力于满足未被覆盖的临床医疗需求。
EXFY vs RIGL — 直观对比
营收规模更大
RIGL
是对方的2.0倍
$35.2M
营收增速更快
RIGL
高出26.1%
-4.9%
两年增速更快
RIGL
近两年复合增速
2.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $35.2M | $69.8M |
| 净利润 | — | $268.1M |
| 毛利率 | 49.2% | 91.5% |
| 营业利润率 | -11.2% | 33.2% |
| 净利率 | — | 384.0% |
| 营收同比 | -4.9% | 21.2% |
| 净利润同比 | — | 1769.2% |
| 每股收益（稀释后） | $-0.07 | $14.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXFYRIGL
| Q4 25 | $35.2M | $69.8M | ||
| Q3 25 | $35.1M | $69.5M | ||
| Q2 25 | $35.8M | $101.7M | ||
| Q1 25 | $36.1M | $53.3M | ||
| Q4 24 | $37.0M | $57.6M | ||
| Q3 24 | $35.4M | $55.3M | ||
| Q2 24 | $33.3M | $36.8M | ||
| Q1 24 | $33.5M | $29.5M |
净利润EXFYRIGL
| Q4 25 | — | $268.1M | ||
| Q3 25 | $-2.3M | $27.9M | ||
| Q2 25 | $-8.8M | $59.6M | ||
| Q1 25 | $-3.2M | $11.4M | ||
| Q4 24 | — | $14.3M | ||
| Q3 24 | $-2.2M | $12.4M | ||
| Q2 24 | $-2.8M | $-1.0M | ||
| Q1 24 | $-3.8M | $-8.2M |
毛利率EXFYRIGL
| Q4 25 | 49.2% | 91.5% | ||
| Q3 25 | 49.6% | 93.2% | ||
| Q2 25 | 51.9% | 95.6% | ||
| Q1 25 | 50.6% | 91.7% | ||
| Q4 24 | 51.0% | 89.9% | ||
| Q3 24 | 51.6% | 85.5% | ||
| Q2 24 | 56.9% | 92.4% | ||
| Q1 24 | 56.5% | 93.1% |
营业利润率EXFYRIGL
| Q4 25 | -11.2% | 33.2% | ||
| Q3 25 | -6.4% | 40.9% | ||
| Q2 25 | -28.9% | 60.1% | ||
| Q1 25 | -4.1% | 23.9% | ||
| Q4 24 | 1.3% | 28.9% | ||
| Q3 24 | 0.8% | 25.4% | ||
| Q2 24 | 0.7% | 1.2% | ||
| Q1 24 | -5.3% | -23.6% |
净利率EXFYRIGL
| Q4 25 | — | 384.0% | ||
| Q3 25 | -6.6% | 40.2% | ||
| Q2 25 | -24.6% | 58.6% | ||
| Q1 25 | -8.8% | 21.5% | ||
| Q4 24 | — | 24.9% | ||
| Q3 24 | -6.2% | 22.5% | ||
| Q2 24 | -8.3% | -2.8% | ||
| Q1 24 | -11.3% | -27.9% |
每股收益（稀释后）EXFYRIGL
| Q4 25 | $-0.07 | $14.11 | ||
| Q3 25 | $-0.03 | $1.46 | ||
| Q2 25 | $-0.10 | $3.28 | ||
| Q1 25 | $-0.03 | $0.63 | ||
| Q4 24 | $-0.03 | $0.82 | ||
| Q3 24 | $-0.02 | $0.70 | ||
| Q2 24 | $-0.03 | $-0.06 | ||
| Q1 24 | $-0.04 | $-0.47 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $63.1M | $155.0M |
| 总债务越低越好 | — | $52.5M |
| 股东权益账面价值 | $132.7M | $391.5M |
| 总资产 | $186.0M | $513.6M |
| 负债/权益比越低杠杆越低 | — | 0.13× |
8季度趋势，按日历期对齐
现金及短期投资EXFYRIGL
| Q4 25 | $63.1M | $155.0M | ||
| Q3 25 | $61.5M | $137.1M | ||
| Q2 25 | $60.5M | $108.4M | ||
| Q1 25 | $59.6M | $77.1M | ||
| Q4 24 | $48.8M | $77.3M | ||
| Q3 24 | $39.2M | $61.1M | ||
| Q2 24 | $53.2M | $49.1M | ||
| Q1 24 | $49.3M | $49.5M |
总债务EXFYRIGL
| Q4 25 | — | $52.5M | ||
| Q3 25 | — | $60.0M | ||
| Q2 25 | — | $60.0M | ||
| Q1 25 | — | $60.0M | ||
| Q4 24 | — | $60.0M | ||
| Q3 24 | — | $60.0M | ||
| Q2 24 | — | $60.0M | ||
| Q1 24 | — | $60.0M |
股东权益EXFYRIGL
| Q4 25 | $132.7M | $391.5M | ||
| Q3 25 | $135.7M | $117.6M | ||
| Q2 25 | $131.8M | $81.9M | ||
| Q1 25 | $134.7M | $18.6M | ||
| Q4 24 | $128.2M | $3.3M | ||
| Q3 24 | $119.9M | $-14.6M | ||
| Q2 24 | $114.0M | $-29.9M | ||
| Q1 24 | $106.5M | $-31.7M |
总资产EXFYRIGL
| Q4 25 | $186.0M | $513.6M | ||
| Q3 25 | $186.8M | $242.5M | ||
| Q2 25 | $187.1M | $206.7M | ||
| Q1 25 | $189.2M | $176.0M | ||
| Q4 24 | $173.7M | $164.0M | ||
| Q3 24 | $176.2M | $139.4M | ||
| Q2 24 | $192.9M | $128.4M | ||
| Q1 24 | $184.8M | $126.5M |
负债/权益比EXFYRIGL
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | 0.51× | ||
| Q2 25 | — | 0.73× | ||
| Q1 25 | — | 3.23× | ||
| Q4 24 | — | 18.25× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $2.2M | $22.0M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | 0.08× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流EXFYRIGL
| Q4 25 | $2.2M | $22.0M | ||
| Q3 25 | $4.2M | $24.0M | ||
| Q2 25 | $8.9M | $30.5M | ||
| Q1 25 | $4.8M | $-893.0K | ||
| Q4 24 | $7.4M | $14.5M | ||
| Q3 24 | $3.7M | $21.7M | ||
| Q2 24 | $9.3M | $302.0K | ||
| Q1 24 | $3.5M | $-5.0M |
资本支出强度EXFYRIGL
| Q4 25 | — | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.0% | — |
现金转化率EXFYRIGL
| Q4 25 | — | 0.08× | ||
| Q3 25 | — | 0.86× | ||
| Q2 25 | — | 0.51× | ||
| Q1 25 | — | -0.08× | ||
| Q4 24 | — | 1.01× | ||
| Q3 24 | — | 1.75× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
